Reply to: "Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment".

Savage, Kevin T; Flood, Kelsey S; Popatia, Sabrina; Golbari, Nicole M; Salian, Prerna; Kimball, Alexa B; Porter, Martina L

Savage, Kevin T; Flood, Kelsey S; Popatia, Sabrina; Golbari, Nicole M; Salian, Prerna; Kimball, Alexa B; Porter, Martina L.

Afiliação

Savage KT; Drexel University College of Medicine, Philadelphia, Pennsylvania.
Flood KS; Harvard Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Popatia S; Baylor College of Medicine, Houston, Texas.
Golbari NM; Stony Brook University School of Medicine, Stony Brook, New York.
Salian P; Harvard Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Kimball AB; Harvard Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Porter ML; Harvard Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts. Electronic address: clears@bidmc.harvard.edu.

J Am Acad Dermatol ; 81(1): e19-e20, 2019 07.

Article em En | MEDLINE | ID: mdl-30914340

Assuntos

Aprovação de Drogas; Estados Unidos; United States Food and Drug Administration

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Aprovação de Drogas País/Região como assunto: America do norte Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google